The Burden of Nasal Inflammation — and the Opportunity for Better Relief

Over 60 million Americans suffer from allergic rhinitis and another 30 million from chronic sinusitis, representing nearly one in four U.S. adults. As shown, allergic rhinitis accounts for 17.9% and chronic sinusitis for 9% of the population — together comprising an enormous and overlapping patient group struggling with nasal inflammation, congestion, and impaired quality of life. Yet, despite the prevalence, current treatments such as sprays and pills often provide incomplete relief because they fail to reach the entire nasal cavity and sinus cavities where inflammation persists. RhineX was designed to address this unmet need — an ENT-engineered, steroid-enhanced nasal rinse that delivers medication where it’s needed most. This large and underserved market represents a significant opportunity to improve outcomes for millions of patients seeking better breathing and lasting relief.